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Growth hormone receptor deficient (GHRD) individuals in Ecuador are cancer free 
their entire lifetime due to low insulin-like growth factor (IGF) levels. This IGF deficiency 
protected that small GHRD population from the wide array of 20 different cancer types that 
caused death in their IGF-replete relatives. This suggests that the initiation or progression of 
many human cancers is dependent on IGF. 
Those GHRD individuals are short statured due to their life-long IGF deficit but 
otherwise are surprisingly healthy and long-lived (some >80 years old). Therefore, we are 
developing IGF-suppressive vaccines for use in fully grown adults with the hope of gaining 
the same potent anti-cancer impact seen in low IGF individuals with GHRD.  
This compelling human example of the cancer prevention benefits of low IGF activity 
coupled with its probable safety in physically mature people form the basis of our 
unprecedented cancer suppression strategy. We designed specific vaccines to prevent the 
emergence of age-dependent cancers by cutting off their essential early supply of IGF.  
Our vaccines actively induce antibodies to neutralize IGF directly or obstruct the 
activity of a key enzyme that regulates IGF bioavailability. Protective vaccination would be 
initiated at middle age since most human cancers occur beyond age 60 and since this 
postponement will circumvent any impairment of normal growth or other functions. The 
continuous presence of those inhibitory antibodies will keep IGF activity at a constantly low 
level and thereby preemptively block the development of incipient cancers later in life.  
These prevention vaccines could be used:  
1) for people with a genetically high likelihood for developing familial forms of cancer, 
       2) as an adjuvant therapy following precancerous growth removal,  
3) to inhibit the recurrence of disease for cancer patients who are in remission, and  
       4) as a general prophylactic to protect against spontaneous, age-dependent cancers. 
 
 
